GC Genome Corporation (KOSDAQ:340450)
South Korea · Delayed Price · Currency is KRW 8,860.00
-240.00 (-2.64%)
At close: Feb 6, 2026
GC Genome Revenue
GC Genome had revenue of 8.84B KRW in the quarter ending September 30, 2025, with 45.98% growth. This brings the company's revenue in the last twelve months to 30.79B. In the year 2024, GC Genome had annual revenue of 25.89B, down -5.15%.
Revenue (ttm)
30.79B
Revenue Growth
-5.15%
P/S Ratio
6.81
Revenue / Employee
n/a
Employees
n/a
Market Cap
209.55B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 25.89B | -1.40B | -5.15% |
| Dec 31, 2023 | 27.29B | 3.18B | 13.18% |
| Dec 31, 2022 | 24.11B | 5.62B | 30.36% |
| Dec 31, 2021 | 18.50B | 4.94B | 36.46% |
| Dec 31, 2020 | 13.56B | 1.40B | 11.51% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.56T |
| Celltrion | 3.90T |
| Jeil Pharmaceutical Co.,Ltd | 621.98B |
| Vieworks | 230.52B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |
| REYON Pharmaceutical | 149.34B |
| Interojo | 109.28B |